J Liver Cancer.  2022 Mar;22(1):1-3. 10.17998/jlc.2022.03.15.

Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?

• Choe WH

• KMID: 2528290
• DOI: http://doi.org/10.17998/jlc.2022.03.15

Reference

References

1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018; 391:1301–1314.

2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69:182–236.

3. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012; 57:821–829.

4. Altayar O, Shah R, Chang CY, Falck-Ytter Y, Muir AJ. AGA technical review on systemic therapies for hepatocellular carcinoma. Gastroenterology. 2022; 162:937–951.

5. Mähringer-Kunz A, Steinle V, Düber C, Weinmann A, Koch S, Schmidtmann I, et al. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: the more, the worse? Liver Int. 2019; 39:324–331.

6. Salgia R, Mendiratta V. The multidisciplinary management of hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2021; 17:405–408.

7. Cho Y, Kim BH, Kim TH, Koh YH, Park JW. Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria. J Liver Cancer. 2022; 22:63–68.

8. Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2014; 88:1041–1047.

9. Park MK, Yu SJ. Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report. J Liver Cancer. 2022; 22:69–74.

10. Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021; 18:525–543.

11. Lee A, Lee J, Yang H, Sung SY, Jeon CH, Kim SH, et al. Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma. J Liver Cancer. 2022; 22:75–83.

12. Kim IJ, Yoo SH, Lee JI, Lee KS, Lee HW, Lim JH. Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report. J Liver Cancer. 2022; 22:84–90.

13. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012; 255:405–414.

14. Schlitt HJ, Hackl C, Lang SA. ‘In-situ split’ liver resection/ALPPS - historical development and current practice. Visc Med. 2017; 33:408–412.

15. Torimura T, Iwamoto H. Optimizing the management of intermediate-stage hepatocellular carcinoma: current trends and prospects. Clin Mol Hepatol. 2021; 27:236–245.